Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Robotic Surgical Approaches Advance Treatment in NSCLC

December 21st 2018

Robert J. Cerfolio, MD, discusses how the use of surgery has significantly evolved over the years and how advances made in robotic surgery improve quality of life of those who need to undergo these procedures.

FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC

December 21st 2018

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 Expression

December 18th 2018

Amishi Desai, MD, assistant professor of medicine at Upstate University Hospital, discusses the use of immunotherapy in patients with non–small cell lung cancer (NSCLC) with PD-L1 expression less than 1%.

Dr. Brahmer on Biomarkers for Immune Response in NSCLC

December 18th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.

Real-World irAEs May Be Higher Than Trial Data Indicate

December 18th 2018

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.

Expert Highlights Utility of PD-L1 to Select Immunotherapy in NSCLC

December 14th 2018

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Dr. Paul Discusses the Pulmonologist's Role in Managing Patients With Lung Cancer

December 14th 2018

Manju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).

Pulmonologist Highlights Latest Diagnostic and Staging Techniques in Lung Cancer

December 13th 2018

Manju P. Paul, MD, discusses new diagnostic and staging techniques that are advancing standards of care in patients with lung cancer.

Dr. Wolf Discusses the GEOMETRY Study in MET+ NSCLC

December 13th 2018

Juergen Wolf, MD, medical director, Center for Integrated Oncology, University Hospital of Cologne, Köln Bonn, Köln, Germany, discusses the GEOMETRY study in patients with MET-positive non–small cell lung cancer (NSCLC).

Despite Success With Targeted Therapies in NSCLC, Drug Resistance Remains Issue

December 12th 2018

Stephen L. Graziano, MD, discusses available and emerging targeted therapies for common driver mutations in patients with non–small cell lung cancer and the sequencing strategies beyond frontline treatment.

PACIFIC Trial Changes Standard of Care in Stage III NSCLC

December 12th 2018

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Experts Highlight Developments in Lung, GI Cancers

December 11th 2018

Recent data have moved the needle across the board in oncology, specifically with lung cancer and gastrointestinal cancers, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes.

Direct Targeting of RET Aberrations Moves Closer to the Clinic

December 11th 2018

Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.

Dr. Sabari Compares Liquid and Tissue Biopsies in NSCLC

December 11th 2018

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.

Neoadjuvant Immunotherapy Has Potential in Stage IIIa NSCLC

December 7th 2018

Nisha A. Mohindra, MD, discusses the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLC

December 7th 2018

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

FDA Approves Frontline Atezolizumab Regimen for NSCLC

December 7th 2018

The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.

Phase III Rova-T Trial Halted in Small Cell Lung Cancer

December 7th 2018

The phase III TAHOE trial evaluating second-line rovalpituzumab tesirine as a treatment for patients with advanced small cell lung cancer has stopped enrollment as recommended by an Independent Data Monitoring Committee.

Dr. Cerfolio on Minimally Invasive Surgery in NSCLC

December 5th 2018

Robert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.

FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC

December 5th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.